Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from a Phase 2b clinical trial. The company announced it will study these topline data in deciding next steps for PTI-125 as a potential treatment. Alzheimer’s disease…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
Potential Agitation Treatment, AXS-05, Shows Efficacy and Safety in Phase 2/3 Trial
Axsome Therapeutics‘ investigational oral therapy AXS-05 significantly and rapidly lessened agitation in patients with Alzheimer’s disease, top-line results from a Phase 2/3 trial show. The therapy was also found to be generally well-tolerated and safe, without affecting cognition. “I am very pleased to see the promising results of the ADVANCE-1 trial, providing clear evidence of reduced agitation…
Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk
Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The results were published in Neurology in a study, titled “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.” Aspirin is a widely-used anti-inflammatory medication. Among its uses, low-dose daily…
Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak
FFF Enterprises and BioNews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of critical-care biopharmaceuticals, plasma products and…
Alzheimer’s Caregivers Often Fear Contracting the Disease
A wise man once said, “No one by worrying can add one inch to their height.” Constantly worrying about acquiring an admittedly horrible disease may be useless, but it also is common practice for caregivers. Our intimate involvement in the daily processes of a disease, and seeing how it affects our loved ones affects us,…
Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that we would learn how valuable…
FDA Filing of Alzheimer’s Therapy Aducanumab Delayed to Late 2020, Biogen Says
Biogen is pushing back the submission of aducanumab, its investigational treatment for Alzheimer’s disease, to the U.S. Food and Drug Administration (FDA) to the third quarter of this year due to the COVID-19 pandemic, the company announced. “The COVID-19 pandemic has created a challenging situation for people and companies throughout the world, and Biogen personally…
Anticipating Summer Solstice in Support of Alzheimer’s Funding
It helps to have something on the back burner, something to anticipate in the days, weeks, and months ahead. We need something on which to place our concentration, other than COVID-19. Summer solstice is that thing. Not the day so much, but the annual event surrounding it. Alzheimer’s Association Continues ‘Longest Day’ Since 2012, the…
Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path
Data from Lundbeck’s Phase 2 and 3 clinical trials of idalopirdine in Alzheimer’s patients, will be made available to researchers worldwide through the Critical Path for Alzheimer’s Disease (CPAD) consortium database, held by The Critical Path Institute (C-Path). The Phase 3 studies failed to meet their primary goals of improving cognitive abilities in those given this treatment. C-Path is…
Let’s Celebrate Togetherness While Flattening the Curve
“As iron sharpens iron, so one person sharpens another.” –King Solomon This COVID-19 journey has become a long one. Did any of us have an idea it would go this far? I doubt it, and yet here we are. Some of us might be a little worse for wear, but my hope is that we’re…
Phase 2/3 Trial of Treatment for Agitation in Alzheimer’s to Conclude Early
Axsome Therapeutics is planning to complete its ADVANCE-1 clinical trial, evaluating AXS-05 as a treatment for agitation in Alzheimer’s disease, a few months earlier to ensure the safety of study participants during the COVID-19 pandemic. Topline results from this Phase 2/3 trial, which opened in 2017, are now expected in April or May, rather than later this…
More Telemedicine Is a Good Thing
Turning our attention away from the all-intrusive pandemic (at least from the primary topics surrounding COVID-19), it’s good to take a minute from the turmoil of the virus to engage with something positive. The continual waves of uncertainty that drive COVID-19 may leave something positive in the disease’s painful wake, particularly for people with Alzheimer’s…